Synmosa and Kyorin announced License Agreement of Imidafenacin- Patented New Drug for OAB

Date:2015.08.31

Synmosa Biopharma has been successfully in-licensed patented new drugs from Japan to Taiwan. Today, Synmosa announced an Exclusive License Agreement with KYORIN Pharmaceutical Co., Ltd for the patented technology, manufacturing and distribution of a new drug in Taiwan. Synmosa is developing a growing portfolio of urology medications with a focus on the manufacturing, in-licensing, and distribution of the new drugs and generics that target unmet medical needs. Trusted by the patients and medical professionals, Synmosa is No1. for OAB medications in Taiwan.

According to a large-scale Chinese EPIC study surveyed in China, Hong Kong and Taiwan, the prevalence of OAB (overactive bladder) is 15.8 percent in both sex; another EPIC study surveyed in Taiwan also found 16.9% of Taiwan populations suffer from OAB, and it increases by aging. OAB symptoms include urgency to urinate, frequency of urination, incontinence, and nocturia which linked to negative emotionality, poor sleep quality, diminished workplace productivity, social relationships, and so on, affecting patient’s quality of life tremendously.

The Agreement between Synmosa and KYORIN Pharmaceutical Corporation anticipates the need for an alternative treatment of OAB in Taiwan. The new drug, Imidafenacin, is a novel anticholinergic agent that acts as a selective antagonist on M3 and M1 muscarinic subtype receptors to improve the urgency of urination, pollakiuria and urge urinary incontinence associated with OAB. Imidafenacin selectively acts on the bladder, and therefore the side effects such as constipate and dry mouth are rather small. Imidafenacin has been well-received and trusted by patients and medical professionals since launched under the brand names Uritos® in 2007 in Japan. The net sales for FY 2014 (Apr 1,2014~Mar 31, 2015) of Uritos is NT.19.2 billion.

Synmosa and Kyorin both specialize in the field of urology and respiratory. With this Agreement on OAB medication-Uritos® (Imidafenacin), Synmosa will expand the integrated product portfolio and provide more comprehensive solution for urologic diseases. The clinical trial of Imidafenacin will soon be conducted at more than 9 medical centers in Taiwan and Hong Kong to speed up the launch of Uritos® in Taiwan.